Glecirasib

Glecirasib (JAB-21822) is Jacobio Pharmaceuticals' covalent KRAS G12C inhibitor, approved in China in August 2024 as Erica for previously treated KRAS G12C-mutated non-small cell lung cancer [1][9]. It joins sotorasib (Amgen's Lumakras) and adagrasib (Bristol Myers' Krazati) as the third approved drug in this mechanism class globally, and the first KRAS G12C inhibitor developed and approved in China. The pipeline question now is whether Jacobio can take glecirasib outside China and whether combination strategies - with the SHP2 inhibitor sitneprotafib (JAB-3312) in NSCLC [2] and cetuximab in colorectal cancer [3] - outperform monotherapy in tumor types where single-agent KRAS G12C inhibition has been underwhelming. Allist Pharmaceuticals runs several of the combo trials in China; Jacobio remains the originator and Chinese marketing authorization holder. The Phase 2b NSCLC monotherapy data showed an ORR of 47.9% and median duration of response of 11.9 months - competitive with sotorasib and adagrasib [1]. The real test is combination data in pancreatic and colorectal cancer, both indications where the current G12C drugs have failed to move the needle commercially - and where, for CRC, glecirasib + cetuximab now competes against an FDA-approved comparator (adagrasib + cetuximab, accelerated approval June 2024) rather than against trial data alone [14]. No FDA filing for glecirasib has been publicly disclosed.

Approved by China NMPA in August 2024 as Erica for KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy [9]. Globally investigational. No FDA filing, breakthrough therapy designation, or fast track status has been publicly disclosed. ChEMBL still lists max_phase 2, a common artifact for Chinese-originated drugs whose regional approval doesn't propagate to Western databases. Ongoing combination programs: NCT05288205 (glecirasib + sitneprotafib in solid tumors, with NSCLC Phase 1/2a data published in Lancet Respir Med 2026) [2][5]; NCT05194995 (glecirasib + cetuximab in KRAS G12C-mutated CRC, Phase 1/2, two protocol cohorts JAB-21822-1002 and JAB-21822-1007 within a single registration) [6]; NCT06008288 (Phase 2 monotherapy in pancreatic and other solid tumors, recruiting, n=88) [7]; and NCT05009329 (Phase 1 in Chinese patients with advanced solid tumors, n=315, active not recruiting) [8]. Expected readouts: key combination NSCLC data within 12-18 months, pancreatic Phase 2 data likely 2027. No publicly announced global Phase 3 randomized trial. China NMPA new-drug data exclusivity (6 years for new chemical entities under the 2020 Drug Administration Law framework) provides protection on the Chinese label; composition-of-matter patents extend further but the exact expiry is not in public Jacobio filings. Per Jacobio's 2025 annual disclosure, the company held approximately RMB 1.53 billion in cash, equivalents, and available credit at year-end 2025, and disclosed approximately RMB 2.1 billion (~US$290M) by May 2026 following a US$100 million upfront from an AstraZeneca collaboration; management guides to ≥4 years of runway [15]. Erica royalty payments from Allist totaled only RMB 8.55 million for June-December 2025, confirming the Chinese launch is not yet a material revenue contributor.

KRAS is a protein that acts like an on/off switch for cell growth. In its normal state it cycles between 'on' (bound to GTP) and 'off' (bound to GDP). When KRAS is mutated at codon 12 - specifically G12C, where the normal glycine becomes a cysteine - the switch gets stuck in the 'on' position too long, and cells keep dividing. The cysteine swap is what makes this mutation druggable: cysteine has a reactive sulfur atom that doesn't exist in wild-type KRAS, so a drug can latch onto it without sticking to the normal protein. Glecirasib, like sotorasib and adagrasib, is a covalent inhibitor that binds irreversibly to that mutant cysteine in the GDP-bound (off) state, locking the switch off. The mechanism is genetically validated: KRAS G12C mutation drives roughly 13% of NSCLC, 3-4% of colorectal cancer, and 1-2% of pancreatic adenocarcinoma. Two prior approvals (Lumakras in 2021, Krazati in 2022) prove the chemistry works in NSCLC. Acquired resistance is the central limitation of the class: tumors that initially respond reactivate MAPK signaling through (i) secondary KRAS mutations including Y96D/S (drug-binding pocket) and switch-II mutations, plus emergent G12D/V/R subclones; (ii) upstream reloading of KRAS-GTP via EGFR, SOS1, MET, FGFR, or HER2 amplification; and (iii) bypass through PI3K/AKT or YAP/TAZ. In NSCLC, STK11 co-mutation (≈20-25% of KRAS-mutant lung adenocarcinomas) and KEAP1 co-mutation (≈10-20%) are the strongest negative predictors of response to KRAS G12C monotherapy. That resistance biology is the entire scientific rationale for combinations: SHP2 inhibition (sitneprotafib) blocks upstream GTP-reloading at the node where most RTK signals converge, and anti-EGFR (cetuximab) blocks the dominant RTK reactivation pathway in CRC, where EGFR-driven feedback is the well-characterized escape mechanism. What remains unsettled is whether glecirasib's potency, brain penetration, or off-target profile gives it an edge over sotorasib and adagrasib. No direct head-to-head data exist, but published response rates look similar to sotorasib [1][4]. The differentiator, if there is one, will come from combinations rather than monotherapy.

NCT05288205 is the central pipeline trial: an open-label Phase 1/2a evaluation of glecirasib in combination with sitneprotafib (JAB-3312, a SHP2 inhibitor) in patients with KRAS G12C-mutated solid tumors [5]. SHP2 is a phosphatase that sits upstream of KRAS in the signaling pathway. Blocking SHP2 limits the supply of GTP-loaded KRAS that escapes G12C inhibition, suppressing the rebound activation that shortens monotherapy durability - the same resistance mechanism described above. The NSCLC portion was published in Lancet Respir Med 2026 (Zhong et al.), single-arm, multicenter, China-only enrollment, with safety/tolerability and ORR by independent central review as primary endpoints [2]. For the colorectal combination with cetuximab (anti-EGFR), JAB-21822-1002 and JAB-21822-1007 are two cohorts within a single Phase 1/2 trial (NCT05194995) reported in Lancet Gastroenterol Hepatol 2026 (Li et al.) [3][6] - not two separately registered protocols. All key data published to date come from single-arm Chinese trials. NCT06008288 is the Phase 2 pancreatic monotherapy program, n=88, ORR by IRC primary, currently recruiting [7]. FDA will likely require randomized confirmatory data with substantial non-Chinese enrollment before considering approval - similar pushback derailed Innovent/Lilly's sintilimab BLA in 2022, and the precedent applies directly to a Chinese-origin oncology asset. The CRC combination program faces an additional hurdle: adagrasib + cetuximab received FDA accelerated approval for previously treated KRAS G12C-mutated mCRC on 21 June 2024 [14], so the registrational comparator for glecirasib + cetuximab outside China is no longer chemotherapy but an approved targeted combination.

The model estimates a 72% chance this drug is eventually approved. It starts from the historical approval rate for drugs at this filing stage, about 84%, then adjusts based on ten facts about the trial and sponsor. The estimate rises because of a non-randomized design and open-label blinding, and falls because of the sponsor's thin approval record and weak earlier-phase results. Most other factors were close to average and left the estimate near where the base rate started.

Efficacy risk: in colorectal cancer, adagrasib + cetuximab has FDA accelerated approval based on a registrational ORR of 34% in KRYSTAL-1 [10][14]. Glecirasib + cetuximab needs to match or beat that with better tolerability to find commercial space, and is now competing against an approved combination rather than against trial data. Pancreatic KRAS G12C is 1-2% of pancreatic patients, and historical monotherapy response rates are ~20% with no clear evidence that combinations rescue the indication. Safety risk: SHP2 inhibitors as a class show edema, thrombocytopenia, and GI toxicity. Revolution Medicines and Sanofi dropped RMC-4630, and TNO155 development at Novartis has been slow. The Shi et al. Phase 2b NSCLC monotherapy data reported overall Grade 3-4 treatment-related adverse events in 38.7% (46/119) of patients, with the predominant Grade 3+ events being hepatotoxicity (ALT/AST elevation) and hypertriglyceridemia; the authors note higher rates of Grade 3+ hepatotoxicity for glecirasib than for sotorasib or adagrasib at comparable timepoints [1]. Layering SHP2 blockade onto a regimen with a higher baseline hepatotoxicity signal is a meaningful clinical risk that the combination data must address. Execution risk: Jacobio has no FDA-approved drug, no US clinical infrastructure, and key data thus far have been generated entirely in Chinese populations. The 2022 sintilimab BLA refusal established that FDA will not accept China-only data for solid tumor approval without strong justification. Commercial risk: KRAS G12C is now a crowded market. Sotorasib has posted lackluster commercial uptake (Lumakras 2024 revenue around $290M per Amgen disclosure) [11], adagrasib is similarly muted, and Revolution Medicines' pan-RAS inhibitor RMC-6236 (daraxonrasib) is in Phase 3 and threatens to eclipse the entire G12C-selective class in pancreatic and colorectal cancer [12]. Financing risk is partially mitigated: Jacobio disclosed approximately RMB 2.1 billion (~US$290M) in cash and equivalents by May 2026 after a US$100M AstraZeneca upfront and guides to ≥4 years runway, which is enough to fund initial global development without imminent dilutive financing [15] - but a randomized global Phase 3 in PDAC or CRC would likely require partnership economics.

Watch, don't chase. The combination strategy is scientifically defensible - SHP2 + G12C is the most biologically grounded pairing - but Jacobio (HKEX:1167; ticker verified against HKEX listing) faces a wall outside China. Specific signal to watch: disclosure of FDA pre-IND meetings or a global Phase 3 randomized design for glecirasib combinations. A co-development deal with a US/EU partner for global registration would move this from interesting-Chinese-asset to globally investable; the May 2026 AstraZeneca collaboration is a positive directional signal even though it is not specifically a glecirasib global rights deal. Without an explicit glecirasib partnership, the asset is a Chinese-market drug with academic-quality global combination data. Check back: Q4 2026 for global development announcements or randomized Phase 3 combination readouts, and watch Revolution Medicines' RMC-6236 Phase 3 PDAC readout in 2026-2027 - if pan-RAS works, the entire G12C-selective class becomes a niche play [12]. For Jacobio specifically, the disclosed cash position (~RMB 2.1B / ≥4 years runway) means Erica's Chinese launch does not have to fund global development in the near term, so dilution risk on a 12-18 month horizon is lower than the prior writeup implied. Best near-term catalyst on the competitor side: Phase 3 KRYSTAL-10 (adagrasib + cetuximab vs chemotherapy) readout, which will set the bar that glecirasib + cetuximab must clear [13].